Supplementary Online Content
|
|
|
- Eunice Harvey
- 5 years ago
- Views:
Transcription
1 Supplementary Online Content Valle JA, Tamez H, Abbott JD, et al. Contemporary use and trends in unprotected left main coronary artery percutaneous coronary intervention in the United States: an analysis of the National Cardiovascular Data Registry Research to Practice initiative. JAMA Cardiol. Published online January 2, doi: /jamacardio etable 1. Demographic and clinical characteristics of patients undergoing ULM PCI over time etable 2. Procedural characteristics of ULM PCI over time etable 3. Clinical outcomes of patients undergoing ULM PCI over time etable 4. Clinical outcomes of patients undergoing ULM PCI stratified by tertile of operator and institutional annual PCI volumes and by tertile of institutional use of mechanical circulatory support etable 5. Baseline characteristics and outcomes in patients who underwent left main PCI in the NCDR, EXCEL trial, and NOBLE trial efigure 1. Cohort creation efigure 2. Factors associated with increased rates of major adverse cardiac events after multivariate adjustment This supplementary material has been provided by the authors to give readers additional information about their work.
2 etable 1. Demographic and clinical characteristics of patients undergoing ULM PCI over time Demographics 2009Q3 2011Q2 2011Q3 2013Q2 2013Q3 2015Q2 2015Q3 2016Q2 N = 6686 N = 8954 N = N = 6829 Age 71.6 ± ± ± ± 12.1 Male gender 3996 (59.8) 5402 (60.3) 6425 (60.3) 4052 (59.3) 0.54 Race White African Am. Asian Other 5904 (88.3) 423 (6.3) 222 (3.3) 67 (1.0) 7705 (86.1) 646 (7.2) 384 (4.0) 118 (1.3) 9140 (85.7) 850 (8.0) 415 (3.9) 122 (1.1) 5846 (85.6) 494 (7.2) 283 (4.1) 94 (1.3) P Hispanic ethnicity 347 (5.2) 498 (5.6) 596 (5.6) 418 (6.1) 0.13 Insurance payor None Private Medicare Medicaid Military Other History 180 (2.7) 4136 (61.9) 4639 (69.4) 733 (11.0) 218 (3.3) 115 (1.7) 324 (3.6) 5658 (63.2) 6067 (67.8) 1016 (11.3) 279 (3.0) 121 (1.3) 284 (2.7) 6800 (63.8) 7512 (70.5) 1307 (12.3) 371 (3.5) 152 (1.4) 151 (2.2) 4351 (63.7) 4895 (71.7) 874 (12.8) 241 (3.5) 113 (1.7) Current tobacco 1313 (19.7) 1768 (19.8) 2063 (19.4) 1304 (19.1) 0.71 Hypertension 5679 (84.9) 7666 (85.6) 9189 (86.2) 4963 (87.3) Dyslipidemia 5246 (81.4) 7267 (81.3) 8625 (81.1) 5529 (81.0) 0.94 Family History CAD b 1164 (17.4) 1599 (17.9) 1643 (15.4) 912 (13.4) Prior MI c 2197 (32.9) 3006 (33.6) 3698 (34.7) 2361 (34.6) 0.05 Prior Heart Failure 1629 (24.4) 2307 (25.8) 3136 (29.4) 2104 (30.8) Prior PCI 2537 (37.9) 3292 (36.8) 3980 (37.3) 2593 (38.0) 0.34 ESRD d on Dialysis 332 (5.0) 484 (5.4) 601 (5.6) 432 (6.3) 0.01 GFR e (mean ± SD) 64.7 ± ± ± ± 20.9 Cerebrovascular Disease 1425 (21.3) 1869 (20.9) 2330 (21.9) 1529 (22.4) 0.11 Peripheral Arterial Disease 1493 (22.3) 1910 (21.3) 2337 (21.9) 1484 (21.7) 0.50
3 Chronic Lung Disease 1597 (23.9) 2210 (24.7) 2643 (24.8) 1656 (24.2) 0.52 Diabetes Mellitus 2568 (38.4) 3567 (39.8) 4369 (41.0) 2864 (41.9) Presentation PCI Status Elective Urgent Emergent Salvage 2779 (41.6) 3203 (47.9) 652 (9.8) 49 (0.7) 3262 (36.4) 4739 (52.9) 893 (10.0) 59 (0.7) 3392 (31.8) 6090 (57.2) 1073 (10.1) 97 (0.9) 2062 (30.2) 4059 (59.5) 647 (9.5) 58 (0.8) CAD presentation No symptoms Unlikely ischemic Stable angina Unstable Angina Non STEMI STEMI 966 (14.5) 179 (7.2) 1076 (16.1) 2607 (39.0) 1427 (21.4) 428 (6.4) 893 (10.0) 204 (2.3) 1263 (14.1) 3797 (42.4) 2163 (24.2) 631 (7.0) 877 (8.2) 279 (2.6) 1292 (12.1) 4562 (42.8) 2867 (26.9) 781 (7.3) 538 (7.9) 198 (2.9) 788 (11.5) 2915 (42.7) 1907 (27.9) 481 (7.0) CCS f Class (2 weeks) Anti anginal medications 1205 (18.1) 352 (5.3) 1143 (17.1) 2147 (32.2) 1818 (27.3) 1177 (13.2) 264 (3.0) 1086 (12.1) 3165 (35.4) 3247 (36.3) 1278 (12.0) 201 (1.9) 957 (9.0) 3786 (25.6) 4423 (41.6) 849 (12.4) 95 (1.4) 548 (8.0) 2459 (36.1) 2869 (42.1) 5011 (75.0) 7207 (80.5) 8781 (82.4) 5668 (83.1) Heart Failure 1632 (24.4) 2408 (26.9) 3420 (32.1) 2356 (34.5) Cardiomyopathy 1342 (20.1) 2010 (22.5) 2643 (24.8) 1860 (27.2) Risk Model Cath PCI Mortality (%; mean ± SD) 2.2 ± ± ± ± All values reported as n (%) unless otherwise specified. a ULM PCI = unprotected left main coronary artery percutaneous coronary intervention b CAD = coronary artery disease c MI = myocardial infarction d ESRD = end stage renal disease
4 etable 2. Procedural characteristics of ULM PCI over time Arterial Access Site Femoral Brachial Radial 2009Q3 2011Q3 2013Q3 2015Q3 2011Q2 2013Q2 2015Q2 2016Q2 N = 6696 N = 8954 N = N = (94.5) 45 (0.7) 315 (4.7) 7998 (89.3) 52 (0.6) 890 (9.9) 8815 (82.7) 59 (0.6) 1735 (16.3) 5403 (79.1) 24 (0.4) 1383 (20.3) MCS a 1511 (22.6) 2071 (23.1) 2592 (24.3) 1995 (29.2) IABP 1055 (15.8) 1275 (14.2) 1402 (13.2) 806 (11.8) Other MCS 529 (7.9) 898 (10.0) 1315 (12.3) 1281 (18.8) P Contrast Volume (ml; mean ± SD) Fluoroscopy Time (minutes; mean ± SD) ± ± ± ± ± ± ± ± 17.1 Lesion Class C 4901 (73.3) 6555 (73.2) 7721 (73.6) 3691 (75.6) LMCA bifurcation 1 Stent >1 Stent Lesion treated previously Restenosis Stent thrombosis Lesion length (mm; mean ± SD) 523 (7.8) 47 (0.7) 687 (7.7) 54 (0.6) 761 (7.3) 85 (0.8) 347 (7.1) 32 (0.7) ± ± ± ± 59.8 Number of lesions treated (mean ± SD) 2.1 ± ± ± ± 1.1 Multivessel PCI 3135 (46.9) 3930 (43.9) 4877 (45.8) 3693 (54.1) PCI Intravascular ultrasound 1035 (38.6) 1412 (42.5) 1448 (38.7) 662 (38.5) Atherectomy Laser Orbital Rotational 15 (0.2) 0 (0.0) 450 (6.7) 36 (0.4) 0 (0.0) 613 (6.8) 41 (0.4) 76 (0.7) 914 (8.7) 34 (0.7) 144 (3.0) 463 (9.5)
5 Thrombectomy Aspiration Mechanical 124 (1.9) 27 (0.4) 147 (1.6) 34 (0.4) 174 (1.7) 36 (0.3) 59 (1.2) 15 (0.3) Cutting or scoring balloon 684 (10.2) 998 (11.1) 1132 (10.8) 442 (9.1) Number of Stents (mean ± SD) 2.3 ± ± ± ± 1.3 Bare Metal Stents 1382 (20.7) 1602 (17.9) 1293 (12.1) 554 (8.1) Drug Eluting Stents 5594 (83.7) 7640 (85.3) 9603 (90.1) 6389 (93.6) DES b type Co Cr EES c Pl Cr EES d ZES e PES f SES g Other DES >1 DES type 3506 (62.7) 0 (0.0) 412 (7.4) 680 (12.2) 416 (7.4) 6 (0.1) 574 (10.3) 3881 (50.8) 1311 (17.2) 1424 (18.6) 464 (6.1) 11 (0.1) 0 (0.0) 549 (7.2) 3241 (33.7) 3107 (32.4) 2382 (28.4) 55 (0.6) 0 (0.0) 157 (1.6) 661 (6.9) 1390 (21.8) 1860 (29.1) 988 (15.5) 8 (0.1) 0 (0.0) 1846 (28.9) 297 (4.6) All values reported as n (%) unless otherwise specified. a MCS = mechanical circulatory support b DES = drug eluting stent c Co Cr EES = cobalt chromium everolimus eluting stent d Pl Cr EES = platinum chromium everolimus eluting stent e ZES = zotarolimus eluting stent f PES = paclitaxel eluting stent g SES = sirolimus eluting stent
6 etable 3. Clinical outcomes of patients undergoing ULM PCI over time Death, MI a, Stroke or Emergent CABG 2009Q3 2011Q3 2013Q3 2015Q3 2011Q2 2013Q2 2015Q2 2016Q2 N = 6696 N = 8954 N = N = (9.3) 835 (9.3) 950 (8.9) 543 (8.0) Death 295 (4.4) 434 (4.8) 555 (5.2) 359 (5.3) MI 303 (4.5) 411 (4.6) 402 (3.8) 169 (2.5) Stroke 35 (0.5) 35 (0.4) 58 (0.5) 48 (0.7) Emergent CABG b 43 (0.6) 45 (0.5) 46 (0.4) 25 (0.4) P All values reported as n (%) unless otherwise specified. a MI = myocardial Infarction b CABG = coronary artery bypass grafting
7 etable 4. Clinical outcomes of patients undergoing ULM PCI stratified by tertile of operator and institutional annual PCI volumes and by tertile of institutional use of mechanical circulatory support Institutional Annual PCI a Volume ULM PCI b Total per tertile Death, MI c, Stroke or Emergent CABG d Tertile 1 Tertile 2 Tertile 3 P > (11.1) 623 (9.5) 2188 (8.6) Death 80 (6.5) 397 (6.2) 1166 (4.6) MI 63 (5.1) 230 (3.6) 992 (3.9) Stroke 5 (0.4) 32 (0.5) 139 (0.5) Emergent CABG 9 (0.7) 39 (0.9) 111 (0.4) Operator Annual PCI Volume ULM PCI Total per tertile Death, MI, Stroke or Emergent CABG > (14.1) 610 (10.1) 2234 (8.5) Death 64 (8.7) 373 (6.2) 1206 (4.6) MI 46 (6.2) 245 (4.1) 994 (3.8) Stroke 1 (0.1) 35 (0.6) 140 (0.5) Emergent CABG 10 (1.4) 46 (0.8) 103 (0.4) Institutional Use of IABP Death, MI c, Stroke or Emergent CABG d 562 (7.8) 1136 (8.6) 1250 (9.9) Death 333 (4.6) 610 (4.6) 700 (5.5) MI 217 (3.0) 517 (3.9) 551 (4.3) Stroke 39 (0.5) 69 (0.5) 68 (0.5) Emergent CABG 34 (0.5) 60 (0.5) 65 (0.5) Institutional Use of non IABP Mechanical Circulatory Support Death, MI, Stroke or Emergent CABG 277 (10.2) 988 (8.0) 1683 (9.3) Death 157 (5.8) 569 (4.6) 917 (5.1) 0.025
8 MI 100 (3.7) 405 (3.3) 780 (4.3) Stroke 18 (0.7) 56 (0.5) 102 (0.6) Emergent CABG 31 (1.1) 60 (0.5) 68 (0.4) All values reported as n (%) unless otherwise specified. a PCI = percutaneous coronary intervention b ULM PCI = unprotected left main percutaneous coronary intervention c MI = myocardial Infarction d CABG = coronary artery bypass grafting
9 etable 5. Baseline characteristics and outcomes in patients who underwent left main PCI in the NCDR, EXCEL trial, and NOBLE trial Baseline Demographics NCDR a EXCEL NOBLE p value n = 33,128 n = 948 n = 592 Age (mean ± SD) 71.8 ± ± ± 9.9 <.001 Female gender 13,253 (40.0) 226 (23.8) 116 (19.6) <.001 White 28,595 (86.3) 844 (91.5) <.001 BMI b (kg/m 2 ; mean ± SD) 28.7 ± ± ± Diabetes Mellitus 13,368 (40.4) 286 (30.2) 86 (14.5) <.001 Hypertension 28,497 (86.0) 703 (74.5) 386 (65.2) <.001 Smoking, active 6,447 (19.5) 222 (24.1) 108 (18.2) <.001 Previous PCI c 118,1763 (35.4) 174 (18.4) 116 (29.5) <.001 Previous CABG d 0 4 (0.7) Congestive Heart Failure 9,176 (27.7) 67 (7.1) <.001 Indication Acute coronary syndrome 106 (17.0) STEMI 2,321 (7.0) 13 (1.4) 0 (0.0) <.001 NSTEMI 8,364 (25.3) 124 (13.2) <.001 UA e 13,881 (41.9) 228 (24.2) <.001 Stable angina 4,419 (13.3) 500 (53.1) 486 (82.1) <.001 Silent/unlikely to be ischemic 4,134 (12.4) 73 (7.7) <.001 Procedure Characteristics Contrast volume (ml; mean ± SD) ± ± (IQR ) <.001 Fluoroscopy time (minutes; mean ± SD) Anticoagulation 23 ± ± (IQR 11 24) Unfractionated heparin (63.5) 787 (83.0) 411 (72.6) <.001 Bivalirudin (48.4) 338 (35.7) 108 (18.9) <.001 Arterial access site Femoral 28,535 (86.2) 744 (72.9) Radial 4,323 (13.1) 275 (26.9) <.001 Brachial 180 (0.5) 2 (0.2) Number of lesions treated (mean ± SD) 2.0 ± ± ± 1.5 <.001 Number of stents implanted per patient (mean ± SD) 2.2 ± ± 1.5 <.001 Drug eluting stent used 29,226 (88.2) 2,282 (99.8) <.001 Lesion involving bifurcation 14,947 (45.1) 763 (80.5) 508 (87.7) <.001 Two stent technique (% of bifurcation lesions) 6053 (40.5) 187 (36.8) <.001 Multivessel PCI (47.2) 263 (44.4) 0.30
10 Intravascular ultrasound guidance 4557 (39.8) 722 (77.2) 430 (74.9) <.001 Mechanical circulatory support 8,169 (24.7) 53 (5.6) <.001 Outcomes Death, myocardial infarction or stroke 137 (15.4) 137 (23.1) <.001 Death, myocardial infarction or 2,993 (9.0) 46 (4.9) <.001 stroke at 30 days or in hospital Death at 30 days or in hospital 1,643 (5.0) 9 (1.0) 2 (0.0) <.001 Stroke at 30 days or in hospital 176 (0.5) 6 (0.6) Myocardial infarction at 30 days 1,285 (3.9) 37 (3.9) 19 (3.2) 0.73 or in hospital All values reported as n (%) unless otherwise specified. Proportions listed exclude those with missing data from the denominator. For comparison of mean versus median values, mean was assumed to equal median values, and SD estimated as the IQR divided by a NCDR = National Cardiovascular Data Registry b BMI = body mass index c PCI = percutaneous coronary intervention d CABG = coronary artery bypass grafting e UA = unstable angina
11 efigure 1. Cohort creation
12 efigure 2. Factors associated with increased rates of major adverse cardiac events after multivariate adjustment
Lessons learned From The National PCI Registry
Lessons learned From The National PCI Registry w a v e On Behalf of The Publication Committee of the National PCI Registry Objectives & Anticipated Achievements To determine the epidemiology of patients
1. Whether the risks of stent thrombosis (ST) and major adverse cardiovascular and cerebrovascular events (MACCE) differ from BMS and DES
1 Comparison of Ischemic and Bleeding Events After Drug- Eluting Stents or Bare Metal Stents in Subjects Receiving Dual Antiplatelet Therapy: Results from the Randomized Dual Antiplatelet Therapy (DAPT)
LM stenting - Cypher
LM stenting - Cypher Left main stenting with BMS Since 1995 Issues in BMS era AMC Restenosis and TLR (%) 3 27 TLR P=.282 Restenosis P=.71 28 2 1 15 12 Ostium 5 4 Shaft Bifurcation Left main stenting with
Asian AMI Registry Session The 17 th Joint Meeting of Coronary Revascularization (JCR 2017) Busan, Korea Dec 8 th 2017
Asian AMI Registry Session The 17 th Joint Meeting of Coronary Revascularization (JCR 2017) Busan, Korea Dec 8 th 2017 Trends of acute myocardial infarction in Korea from the experience of Korea Acute
New Jersey Cardiac Catheterization Data Registry, Version 2.0 (Please report data only for patients 16 years or older.)
A. ADMINISTRATIVE New Jersey Cardiac Catheterization Data Registry, Version 2.0 (Please report data only for patients 16 years or older.) 1. Facility Code: 2. Facility Name: 3. Procedure Type (Choose only
CPORT E Trial. Atlantic C PORT
CPORT E Trial Randomized trial comparing medical, economic and quality of life outcomes of non primary PCI at hospitals with and without on site cardiac surgery Mo#va#on for Trial Sustain primary PCI program
PROMUS Element Experience In AMC
Promus Element Luncheon Symposium: PROMUS Element Experience In AMC Jung-Min Ahn, MD. University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea PROMUS Element Clinical
The MAIN-COMPARE Study
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
Clinical Study Age Differences in Long Term Outcomes of Coronary Patients Treated with Drug Eluting Stents at a Tertiary Medical Center
Aging Research Volume 2013, Article ID 471026, 4 pages http://dx.doi.org/10.1155/2013/471026 Clinical Study Age Differences in Long Term Outcomes of Coronary Patients Treated with Drug Eluting Stents at
Supplementary Online Content
Supplementary Online Content Inohara T, Xian Y, Liang L, et al. Association of intracerebral hemorrhage among patients taking non vitamin K antagonist vs vitamin K antagonist oral anticoagulants with in-hospital
Supplementary Material to Mayer et al. A comparative cohort study on personalised
Suppl. Table : Baseline characteristics of the patients. Characteristic Modified cohort Non-modified cohort P value (n=00) Age years 68. ±. 69.5 ±. 0. Female sex no. (%) 60 (0.0) 88 (.7) 0.0 Body Mass
Alex versus Xience Registry Preliminary report
Interventional Cardiology Network Alex versus Xience Preliminary report Mariusz Gąsior 1,2, Marek Gierlotka 1, Lech Poloński 1,2 1 3rd Department of Cardiology, Medical University of Silesia Centre tor
Left Main PCI vs. CABG: Real World
Management of Patients with Stable CAD Left Main PCI vs. CABG: Real World Marco Roffi, MD, FESC University Hospital Geneva, Switzerland SYNTAX-LMT The SYNTAX trial included a pre-specified subgroup of
Unprotected LM intervention
Unprotected LM intervention Guideline for COMBAT Seung-Jung Park, MD, PhD Professor of Internal Medicine, Seoul, Korea Current Recommendation for unprotected LMCA Stenosis Class IIb C in ESC guideline
Bern-Rotterdam Cohort Study
Bern-Rotterdam Cohort Study Newer generation everolimus-eluting stents eliminate the risk of very late stent thrombosis compared with early generation sirolimus-eluting and paclitaxel-eluting stents Lorenz
Supplement materials:
Supplement materials: Table S1: ICD-9 codes used to define prevalent comorbid conditions and incident conditions Comorbid condition ICD-9 code Hypertension 401-405 Diabetes mellitus 250.x Myocardial infarction
The MAIN-COMPARE Registry
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
Supplementary Online Content
Supplementary Online Content Schulz Schüpke S, Helde S, Gewalt S; et al. Comparison of vascular closure devices vs manual compression after femoral artery puncture: the ISAR-CLOSURE randomized clinical
Supplementary Table S1: Proportion of missing values presents in the original dataset
Supplementary Table S1: Proportion of missing values presents in the original dataset Variable Included (%) Missing (%) Age 89067 (100.0) 0 (0.0) Gender 89067 (100.0) 0 (0.0) Smoking status 80706 (90.6)
Surgical vs. Percutaneous Revascularization in Patients with Diabetes and Acute Coronary Syndrome
Surgical vs. Percutaneous Revascularization in Patients with Diabetes and Acute Coronary Syndrome Chris C. Cook, MD Associate Professor of Surgery Director, CT Residency Program, WVU ACOI 10/17/18 No Disclosures
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions
Julinda Mehilli, MD Deutsches Herzzentrum Technische Universität Munich Germany ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions Background Left main
10-Year Mortality of Older Acute Myocardial Infarction Patients Treated in U.S. Community Practice
10-Year Mortality of Older Acute Myocardial Infarction Patients Treated in U.S. Community Practice Ajar Kochar, MD on behalf of: Anita Y. Chen, Puza P. Sharma, Neha J. Pagidipati, Gregg C. Fonarow, Patricia
Division of Cardiovascular Medicine, Jichi Medical University Saitama Medical Center, Japan
Association between continuously elevated C-reactive protein and restenosis after percutaneous coronary intervention using drug-eluting stent in angina patients Division of Cardiovascular Medicine, Jichi
Pathology of percutaneous interventions (PCI) in coronary arteries. Allard van der Wal, MD.PhD; Pathologie AMC, Amsterdam, NL
Pathology of percutaneous interventions (PCI) in coronary arteries Allard van der Wal, MD.PhD; Pathologie AMC, Amsterdam, NL Percutaneous Coronary Intervention (PCI) Definition: transcatheter opening of
Rationale for Percutaneous Revascularization ESC 2011
Rationale for Percutaneous Revascularization Marie Claude Morice, Massy FR MD, FESC, FACC ESC 2011 Paris Villepinte - 27-31 August, 2011 Massy, France Potential conflicts of interest I have the following
Table S1: Diagnosis and Procedure Codes Used to Ascertain Incident Hip Fracture
Technical Appendix Table S1: Diagnosis and Procedure Codes Used to Ascertain Incident Hip Fracture and Associated Surgical Treatment ICD 9 Code Descriptions Hip Fracture 820.XX Fracture neck of femur 821.XX
NCDR CathPCI Registry v4.4 Diagnostic Catheterization and Percutaneous Coronary Intervention Registry
A. DEMOGRAPHICS Last Name 2000 : First Name 2010 : Middle Name 2020 : SSN 2030 : - - - SSN N/A 2031 Patient ID 2040 : (auto) Other ID 2045 : Birth Date 2050 : *** @ Sex 2060 : *** @ O Male O Female Race:
PCI for LMCA lesions A Review of latest guidelines and relevant evidence
HCS Working Group Seminars Met Hotel, Thursday 14 th February 2013 PCI for LMCA lesions A Review of latest guidelines and relevant evidence Vassilis Spanos Interventional Cardiologist, As. Director 3 rd
Supplementary Online Content
Supplementary Online Content Amin AP, Spertus JA, Cohen DJ, Chhatriwalla A, Kennedy KF, Vilain K, Salisbury AC, Venkitachalam L, Lai SM, Mauri L, Normand S-LT, Rumsfeld JS, Messenger JC, Yeh RW. Use of
Ischemic Heart Disease Interventional Treatment
Ischemic Heart Disease Interventional Treatment Cardiac Catheterization Laboratory Procedures (N = 11,61) is a regional and national referral center for percutaneous coronary intervention (PCI). A total
Clinical Lessons from BMC2-PCI
Clinical Lessons from BMC2-PCI The Blue Cross Blue Shield of Michigan Cardiovascular Consortium Hitinder Gurm, M.D. University of Michigan Overview 32 papers since inception 10 papers published this year
Evolution In Interventional Cardiology. Jawed Polad Jeroen Bosch Hospital s-hertogenbosch The Netherlands
Evolution In Interventional Cardiology Jawed Polad Jeroen Bosch Hospital s-hertogenbosch The Netherlands 25 November 2010 Coronary Atherosclerosis Timeline in interventional cardiology Indications for
Supplementary Online Content
Supplementary Online Content Khera R, Dharmarajan K, Wang Y, et al. Association of the hospital readmissions reduction program with mortality during and after hospitalization for acute myocardial infarction,
Ischemic Heart Disease Interventional Treatment
Ischemic Heart Disease Interventional Treatment Cardiac Catheterization Laboratory Procedures (N = 89) is a regional and national referral center for percutaneous coronary intervention (PCI). A total of
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE)
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE) Review of TA152 drug-eluting stents for the treatment of coronary artery disease (part review of TA71) this guidance was originally
Supplementary Online Content
Supplementary Online Content Leibowitz M, Karpati T, Cohen-Stavi CJ, et al. Association between achieved low-density lipoprotein levels and major adverse cardiac events in patients with stable ischemic
Medicine OBSERVATIONAL STUDY
Medicine OBSERVATIONAL STUDY It Is Not Mandatory to Use Triple Rather Than Dual Anti-Platelet Therapy After a Percutaneous Coronary Intervention With a Second-Generation Drug-Eluting Stent Ju-Youn Kim,
Safety-outcomes of bioresorbable Everolimus eluting scaffold in (German-Austrian-ABSORB RegIsteR)
Safety-outcomes of bioresorbable Everolimus eluting scaffold in 2168 patients with CAD: 30 days follow-up from the GABI-R (German-Austrian-ABSORB RegIsteR) C. Hamm, University of Giessen, Germany on behalf
Summary HTA. Drug-eluting stents vs. coronary artery bypass-grafting. HTA-Report Summary. Gorenoi V, Dintsios CM, Schönermark MP, Hagen A
Summary HTA HTA-Report Summary Drug-eluting stents vs. coronary artery bypass-grafting in coronary heart disease Gorenoi V, Dintsios CM, Schönermark MP, Hagen A Scientific background The coronary heart
Index. Note: Page numbers of article titles are in boldface type.
Cardiol Clin 24 (2006) 299 304 Index Note: Page numbers of article titles are in boldface type. A Abciximab in PCI, 180 182 ACE trial, 182 Actinomycin D-eluting stent, 224 ACUITY trial, 190 Acute myocardial
Gender-Based Outcomes in Percutaneous Coronary Intervention with Drug-Eluting Stents (from the National Heart, Lung, and Blood Institute Dynamic
Gender-Based Outcomes in Percutaneous Coronary Intervention with Drug-Eluting Stents (from the National Heart, Lung, and Blood Institute Dynamic Registry) J. D. Abbott, et al. Am J Cardiol (2007) 99;626-31
From the a Duke Clinical Research Institute, Durham, NC, Singapore, Singapore,
Comparison of percutaneous coronary intervention for previously treated versus de novo culprit lesions in acute myocardial infarction patients: insights from the National Cardiovascular Data Registry Chee
Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents
Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents Prof. Dr. med. Julinda Mehilli Medizinische Klinik und Poliklinik I Klinikum der Universität München Campus Großhadern Key Factors
Mid-term results from real-world REPARA registry. Felipe Hernandez, on behalf of the REPARA investigators
Mid-term results from real-world REPARA registry Felipe Hernandez, on behalf of the REPARA investigators Potential conflicts of interest Speaker's name: Felipe Hernandez I have the following potential
Jun-Won Lee, Sang Wook Park, Jung-Woo Son, Young Jin Youn, Min-Soo Ahn, Sung Gyun Ahn, Jang-Young Kim, Byung-Soo Yoo, Junghan Yoon, Seung-Hwan Lee
The procedural success and complication rate of the left distal radial approach for coronary angiography and percutaneous coronary intervention. Prospective observational study (LeDRA) Jun-Won Lee, Sang
ANGIOPLASY SUMMIT 2007 TCT ASIA PACIFIC. Seoul, Korea: April The problem is exaggerated: Data from Real World Registries
ANGIOPLASY SUMMIT 007 TCT ASIA PACIFIC Seoul, Korea: 5-7 7 April 007 15 min Plenary Session: State-of of-the-art Lectures The problem is exaggerated: Data from Real World Registries Antonio Colombo Centro
APPENDIX F: CASE REPORT FORM
APPENDIX F: CASE REPORT FORM Instruction: Complete this form to notify all ACS admissions at your centre to National Cardiovascular Disease Registry. Where check boxes are provided, check ( ) one or more
Clinical Outcomes in a Community-Based Single Operator Coronary Interventional Program
Clinical Outcomes in a Community-Based Single Operator Coronary Interventional Program Christian J. Posner, MD, PhD; Carol L. Kaufman, RT(R) (CV) ABSTRACT Background: Physicians who perform fewer than
4. Which survey program does your facility use to get your program designated by the state?
STEMI SURVEY Please complete one survey for each TCD designation you have in your facility. There would be a maximum of three surveys completed if your facility was designated as a trauma, stroke and STEMI
Downloaded from:
Annemans, L; Danchin, N; Van de Werf, F; Pocock, S; Licour, M; Medina, J; Bueno, H (2016) Prehospital and in-hospital use of healthcare resources in patients surviving acute coronary syndromes: an analysis
TCTAP Upendra Kaul MD,DM,FACC,FSCAI,FAMS,FCSI
Indian TUXEDO Trial In Medically Treated Diabetics Upendra Kaul MD,DM,FACC,FSCAI,FAMS,FCSI Executive Director and Dean Escorts Heart Institute & Medical Research Center and Fortis Hospitals, New Delhi
EXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017
EXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017 Igor F. Palacios, MD Director of Interventional Cardiology Professor of Medicine Massachusetts
Benefit of Performing PCI Based on FFR
Benefit of Performing PCI Based on FFR William F. Fearon, MD Associate Professor Director, Interventional Cardiology Stanford University Medical Center Benefit of FFR-Guided PCI FFR-Guided PCI vs. Angiography-Guided
Surgery Grand Rounds
Surgery Grand Rounds Coronary Artery Bypass Grafting versus Coronary Artery Stenting Charles Ted Lord, R1 Coronary Artery Disease Stenosis of epicardial vessels Metabolic & hematologic Statistics 500,000
Three-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G.
Three-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G. Ellis MD Dean J. Kereiakes MD and Gregg W. Stone MD for the ABSORB
Randomized comparison of single versus double mammary coronary artery bypass grafting: 5 year outcomes of the Arterial Revascularization Trial
Randomized comparison of single versus double mammary coronary artery bypass grafting: 5 year outcomes of the Arterial Revascularization Trial Embargoed until 10:45 a.m. CT, Monday, Nov. 14, 2016 David
SCAAR: Lower late and very late stent thrombosis rates with new generation drug eluting stents compared to bare metal stents
SCAAR: Lower late and very late stent thrombosis rates with new generation drug eluting stents compared to bare metal stents Christoph Varenhorst, Giovanna Sarno, Göran Olivecrona, Per Tornvall, Johan
Background. Drug-eluting stents (DES) are increasingly used in complex patients with a high clinical or lesion-related risk of adverse events.
Complex Patients Treated with Second- Generation Zotarolimus-Eluting Resolute and Everolimus-Eluting Xience V Stents in the Randomized TWENTE Trial: Comparison of 2- Year Clinical Outcome Hanim Sen, MD
Chapter 4: Cardiovascular Disease in Patients With CKD
Chapter 4: Cardiovascular Disease in Patients With CKD The prevalence of cardiovascular disease is 68.8% among patients aged 66 and older who have CKD, compared to 34.1% among those who do not have CKD
Osler Journal Club Outcomes Research
Osler Journal Club Outcomes Research Malenka DJ, et al. Outcomes Following Coronary Stenting in the Era of Bare-Metal vs. the Era of Drug- Eluting Stents. JAMA 2008; 299(24):2868-2876 Mentor: Dr. Boulware
In-Ho Chae. Seoul National University College of Medicine
The Earlier, The Better: Quantum Progress in ACS In-Ho Chae Seoul National University College of Medicine Quantum Leap in Statin Landmark Trials in ACS patients Randomized Controlled Studies of Lipid-Lowering
Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD
Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD Mun K. Hong, MD Associate Professor of Medicine Director, Cardiovascular Intervention and Research Weill Cornell
Impact of Chronic Kidney Disease on Long-Term Outcome in Coronary Bypass Candidates Treated with Percutaneous Coronary Intervention
Original Article Print ISSN 1738-5520 On-line ISSN 1738-5555 Korean Circulation Journal Impact of Chronic Kidney Disease on Long-Term Outcome in Coronary Bypass Candidates Treated with Percutaneous Coronary
Supplementary Online Content
Supplementary Online Content Dharmarajan K, Wang Y, Lin Z, et al. Association of changing hospital readmission rates with mortality rates after hospital discharge. JAMA. doi:10.1001/jama.2017.8444 etable
Bifurcation stenting with BVS
Bifurcation stenting with BVS Breaking the limits or just breaking the struts? Maciej Lesiak Department of Cardiology University Hospital in Poznan, Poland Disclosure Speaker s name: Maciej Lesiak I have
SUPPLEMENTAL MATERIAL. Supplemental Methods. Duke CAD Index
SUPPLEMENTAL MATERIAL Supplemental Methods Duke CAD Index The Duke CAD index, originally developed by David F. Kong, is an angiographic score that hierarchically assigns prognostic weights (0-100) based
Chapter 4: Cardiovascular Disease in Patients with CKD
Chapter 4: Cardiovascular Disease in Patients with CKD The prevalence of cardiovascular disease (CVD) was 65.8% among patients aged 66 and older who had chronic kidney disease (CKD), compared to 31.9%
Abstract Background: Methods: Results: Conclusions:
Two-Year Clinical and Angiographic Outcomes of Overlapping Sirolimusversus Paclitaxel- Eluting Stents in the Treatment of Diffuse Long Coronary Lesions Kang-Yin Chen 1,2, Seung-Woon Rha 1, Yong-Jian Li
Long-term outcomes of PCI vs. CABG for ostial/midshaft lesions in unprotected left main coronary artery
Journal of Geriatric Cardiology (2017) 14: 254 260 2017 JGC All rights reserved; www.jgc301.com Research Article Open Access Long-term outcomes of PCI vs. CABG for ostial/midshaft lesions in unprotected
Indications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014
Indications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014 Indications for cardiac catheterization Before a decision to perform an invasive procedure such
STATINS EVALUATION IN CORONARY PROCEDURES AND REVASCULARIZATION
STATINS EVALUATION IN CORONARY PROCEDURES AND REVASCULARIZATION Otávio Berwanger, MD, FACS - On behalf of the SECURE Steering Committee and Investigators Trial Organization Trial Steering Committee Dr.
Revascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease
Impact of Angiographic Complete Revascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease Young-Hak Kim, Duk-Woo Park, Jong-Young Lee, Won-Jang
NCVD-PCI Registry. Percutaneous Coronary Intervention (PCI) Registry, MALAYSIA c/o National Heart Association of Malaysia
NCVD-PCI Registry National Cardiovascular Disease Database (NCVD) National Cardiovascular Disease Database (NCVD) Percutaneous Coronary Intervention (PCI) Registry, MALAYSIA c/o National Heart Association
What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor
76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class
Coronary Artery Stenosis. Insight from MAIN-COMPARE Study
PCI for Unprotected Left Main Coronary Artery Stenosis Insight from MAIN-COMPARE Study Young-Hak Kim, MD, PhD Cardiac Center, University of Ulsan College of Medicine, Asan Medical Center Current Practice
Supplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Weintraub WS, Grau-Sepulveda MV, Weiss JM, et al. Comparative
STEMI update. Vijay Krishnamoorthy M.D. Interventional Cardiology
STEMI update Vijay Krishnamoorthy M.D. Interventional Cardiology OVERVIEW Current Standard of Care in Management of STEMI Update in management of STEMI Pre-Cath Lab In the ED/Office/EMS. Cath Lab Post
TYPE II MI. KC ACDIS LOCAL CHAPTER March 8, 2016
TYPE II MI KC ACDIS LOCAL CHAPTER March 8, 2016 TYPE 2 MI DEFINITION: Acute coronary syndrome (ACS) encompasses a continuum of myocardial ischemia and infarction, which can make the diagnostic and coding
Quality of Life After Everolimus- Eluting Stents or Bypass Surgery for Treatment of Left Main Coronary Artery Disease:
Quality of Life After Everolimus- Eluting Stents or Bypass Surgery for Treatment of Left Main Coronary Artery Disease: Results from the EXCEL Trial Suzanne J. Baron MD MSC on behalf of the EXCEL Investigators
PCI or CABG for severe unprotected left main coronary artery disease: making sense of the NOBLE and EXCEL trials
Editorial PCI or CABG for severe unprotected left main coronary artery disease: making sense of the NOBLE and EXCEL trials Anthony A. Holmes, Sripal Bangalore Leon H. Charney Division of Cardiology, New
Coronary Stent Choice in Patients With Diabetes Mellitus
Rome Cardiology Forum 2014 Coronary Stent Choice in Patients With Diabetes Mellitus Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University
Timing of Surgery After Percutaneous Coronary Intervention
Timing of Surgery After Percutaneous Coronary Intervention Deepak Talreja, MD, FACC Bayview/EVMS/Sentara Outline/Highlights Timing of elective surgery What to do with medications Stopping anti-platelet
Ziyad Ghazzal MD, FACC, FSCAI Professor of Medicine Deputy Vice President/Dean Associate Dean for Clinical Affairs American University of Beirut
Ziyad Ghazzal MD, FACC, FSCAI Professor of Medicine Deputy Vice President/Dean Associate Dean for Clinical Affairs American University of Beirut Adjunct Professor Emory University School of Medicine Indication
Chapter 29 Left Main Intervention in the Light of EXCEL and NOBLE Trials
Chapter 29 Left Main Intervention in the Light of EXCEL and NOBLE Trials DEBDATTA BHATTACHARYYA AYAN KAR The incidence of angiographically significant left main stenosis described in various studies has
Consensus Core Set: Cardiovascular Measures Version 1.0
Consensus Core Set: Cardiovascular s NQF 0330 Hospital 30-day, all-cause, riskstandardized readmission rate (RSRR) following heart failure hospitalization 0229 Hospital 30-day, all-cause, riskstandardized
Rationale for Prophylactic Support During Percutaneous Coronary Intervention
Rationale for Prophylactic Support During Percutaneous Coronary Intervention Navin K. Kapur, MD, FACC, FSCAI Assistant Director, Interventional Cardiology Director, Interventional Research Laboratories
What do the guidelines say?
Percutaneous coronary intervention in 3-vessel disease and main stem What do the guidelines say? Nothing to disclose Dariusz Dudek Institute of Cardiology, Jagiellonian University Krakow, Poland The European
PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia study
ESC, Hotline III, Paris, August, 30, 2011 PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia study M. Valgimigli, MD, PhD University of Ferrara, ITALY On behalf of the
7-Year Follow-up From a Randomized Trial of Sirolimus-Eluting vs. Everolimus-Eluting Stents in Patients With Coronary Artery Disease (RESET)
7-Year Follow-up From a Randomized Trial of Sirolimus-Eluting vs. Everolimus-Eluting Stents in Patients With Coronary Artery Disease (RESET) Hiroki Shiomi, MD Kyoto University Graduate School of Medicine
National Intervention Council
National Intervention Council Cardiological Society of India Registry Performa for Coronary, Non- Coronary & Peripheral Interventions Period January 1st 2016 to December 31 st 2016 Dr. (Prof.) N.N. Khanna
TRIAL UPDATE 1. ISAR TRIPLE SECURITY Trial. Dr Deven Patel Royal Free Hospital
TRIAL UPDATE 1 ISAR TRIPLE SECURITY Trial Dr Deven Patel Royal Free Hospital NO CONFLICT OF INTEREST TO DECLARE ISAR TRIPLE Comparison of 6 weeks vs 6 months Triple Therapy in patients on oral anticoagulation
Relationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome
Relationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome Helder Dores, Luís Bronze Carvalho, Ingrid Rosário, Sílvio Leal, Maria João
Measurement Name Beta-Blocker Therapy Prior Myocardial Infarction (MI)
Program Metrics The list below includes the metrics that will be calculated by the PINNACLE Registry for the outpatient office setting. These include metrics for Artery, Atrial Fibrillation, Hypertension
New Generation Drug- Eluting Stent in Korea
New Generation Drug- Eluting Stent in Korea Young-Hak Kim, MD, PhD Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Purpose To briefly introduce the
Coronary Artery Disease 2017, 28: a Department of Cardiology, University of Ulsan College of Medicine, Asan Medical
Original research 675 Generalizability of EXCEL and NOBLE results to a large registry population with unprotected left main coronary artery disease Pil Hyung Lee a, Se Hun Kang a, Seungbong Han b, Jung-Min
Dual Antiplatelet Therapy Made Practical
Dual Antiplatelet Therapy Made Practical David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management Clinical Associate Professor
Diagnostic & Therapeutic Cardiac Catheterization Coder 2017
Diagnostic & Therapeutic Cardiac Catheterization Coder 2017 Including peripheral and cardiovascular services and procedures Prepared and Published By: MedLearn Publishing A Division of Panacea Healthcare
Observational comparative effectiveness research using large databases
Observational comparative effectiveness research using large databases Robert W. Yeh, MD MSc Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology Beth Israel Deaconess Medical Center
2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium. Seoul National University Hospital Cardiovascular Center
2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium Does Lt Late Cth Catch up Exist Eiti in DES? : Quantitative Coronary Angiography Analysis Kyung Woo Park, MD Cardiovascular
The present status of selfexpanding. for CLI: Why and when to use. Sean P Lyden MD Cleveland Clinic Cleveland, Ohio
The present status of selfexpanding and balloonexpandable tibial BMS and DES for CLI: Why and when to use Sean P Lyden MD Cleveland Clinic Cleveland, Ohio Disclosure Speaker name: Sean Lyden, MD I have